Intercept Pharmaceuticals
Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases.
376 employees · est. 2002 · Morristown, United States
Intercept Pharmaceuticals is the older company (2016 vs 2002); Intercept Pharmaceuticals is the larger of the two.
Side-by-Side Comparison
| Metric | Cerevance | Intercept Pharmaceuticals |
|---|---|---|
| Founded | ||
| Founded | 2016 | 2002 older |
| Headquarters | ||
| Headquarters | Boston, United States | Morristown, United States |
| Employees | ||
| Employees | 35 | 376 larger |
| Industry | ||
| Industry | Biotechnology, Health and Wellness, Life Sciences | Biotechnology, Health Care, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Series C | Post Ipo Debt |
| Total Funding | ||
| Total Funding | $224.00M | $970.05M |
| Funding Rounds | ||
| Funding Rounds | 9 | 8 |
| Services | ||
| Services | Not tracked yet | Not tracked yet |
| Target Customers | ||
| Target Customers | Not tracked yet | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Neuroscience, Pharmaceuticals, Mental Health, Drug Discovery, Neurological Disorders, Brain Research, Psychiatric Diseases, Biopharmaceuticals, Genomics, Neurodegenerative Diseases | Biopharmaceutical, Liver Diseases, Rare Diseases, Drug Development, Therapeutics, Chronic Autoimmune Liver Diseases, Small Molecule Drugs, Fibrotic Diseases, Metabolic Diseases, Bile Acid Receptors, Chronic Liver Diseases, Non-viral Liver Diseases, Innovation |
| Website | ||
| Website | cerevance.com | interceptpharma.com |
About Cerevance
Cerevance is a biotechnology startup that was founded in 2016 and is based in the United States. The company recently secured a substantial $47.00M Series B investment on 25 April 2024. The investors in this round included GV, Lightstone Ventures, Agent Capital, Bioluminescence Ventures, DermBiont,...
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, founded in 2002, is a biopharmaceutical company focused on developing novel therapeutics to treat rare and serious liver diseases such as primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). The company's last investment of $447.70M in Post-IPO...
Be first to know when either one moves
Funding rounds, hiring surges, leadership changes and stack switches at Cerevance and Intercept Pharmaceuticals — tracked continuously, sent the day they land.
Funding, hiring, leadership and stack changes at Cerevance and Intercept Pharmaceutic... — by email.
Frequently Asked Questions
Compare Cerevance with someone else
Start typing a company name or domain.